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Abstract Microinjection of expression plasmids encoding either 
JAK2 or hyperactive (NA661)rJAK2 into serum-starved 
NIH3T3 cells resulted in 20-30-fold induction of DNA 
synthesis. Control microinjections of buffer or parental pcDNA3 
vector resulted in only 3-5-fold induction of DNA synthesis. 
Induction of DNA synthesis was blocked when plasmid encoding 
JAK2 was microinjected in the presence of the JAK2-selective 
inhibitor AG-490, whereas AG-490 did not block DNA synthesis 
induced by microinjected plasmid encoding (NA661)rJAK2. The 
ability of JAK2 to initiate the G0/S cell cycle transition is 
comparable to that of other proto-oncogenes, and supports a 
mechanistic role for overexpressed Janus kinases in carcinogen-
esis. 
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1. Introduction 
The Janus kinases constitute a protein-tyrosine kinase fam-
ily which is crucial for the propagation of cytokine-induced 
signal transduction [1,2]. Under normal conditions, JAK2 is 
converted from a latent to an active kinase by the ligand-
induced activation of receptors for prolactin [3,4], erythro-
poietin [5], growth hormone [6], interleukin-3 [7], granulo-
cyte-macrophage colony stimulating factor [8], cytokines 
such as interleukin-6 which induce gpl30 homodimerization 
[9,10], and other cytokines in cells whose proliferation and/or 
differentiation is dependent upon these ligands. Erythropoie-
tin-induced proliferation can be blocked by the expression of 
catalytically inactive JAK2 [11], suggesting not only that the 
enzyme may possess auto-regulatory domains but also that 
the catalytic activity of the enzyme is an essential component 
of the proliferative signal transduction cascade. Baculovirally 
mediated expression of a JAK2 mutant lacking the putative 
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auto-regulatory domain yields an enzyme which appears to be 
'hyperactive' [12]. Baculoviral expression experiments also 
provide evidence to suggest that as the amount of JAK2 ex-
pressed in a cell increases, the kinase becomes constitutively 
active [8,12,13]. Transient overexpression of JAK1 and JAK2 
in human kidney 293 cells also results in the constitutive acti-
vation of these Janus kinases [14]. It has therefore been pro-
posed that overexpression of Janus kinases, or expression of 
'hyperactive' Janus kinase mutants, may result in cellular 
transformation. 
Recent findings [15,16] substantiate this hypothesis. The 
Tumor-ous-lethal (Tum-l) [17] mutation is an X-linked, domi-
nant mutation in the Drosophila melanogaster hopscotch (hop) 
[18] gene, which encodes a Janus kinase homologue. A point 
mutation converting amino acid residue 341 from glycine to 
glutamic acid has been identified as the hopTum~l defect; this 
mutation was linked to increased tyrosine kinase activity of 
the mutant Hop and the formation of melanotic tumors [15]. 
Further, overexpression of wild-type hop in larval lymph 
glands results in both an increase in Hop tyrosine kinase 
activity and in melanotic tumor formation [15]. A second 
line of evidence supporting the oncogenic nature of Janus 
kinase overexpression derives from analysis of leukaemic cells 
taken from the bone marrow of patients with relapse acute 
lymphoblastic leukaemia (ALL) [16]. Western blot analysis 
indicated that JAK2 was produced at a significantly higher 
level in the ALL cells, as compared to normal T cells, B cells, 
and fibroblasts, and the JAK2 was present in the ALL cells as 
a constitutively active kinase. The constitutive JAK2 activity 
was selectively inhibited by a tyrphostin, AG-490, which also 
inhibited proliferation of ALL cells grown in culture and of 
ALL cells transplanted into SCID mice. 
Viral transformations which allow for cytokine-independent 
growth have been correlated with constitutive activation of 
Janus kinases [19,20]. Abelson murine leukemia virus (A-
MuLV) transformation of pre-B cell lines normally requiring 
interleukin-7 for growth resulted in the constitutive activation 
of JAK 1 and JAK3 [19]. CD4+ T cells infected with human T 
cell lymphotropic virus 1 (HTLV-1) ultimately become inde-
pendent of interleukin-2, a phenomenon associated with the 
constitutive activation of JAK3 [20]. 
Each of these four experimental systems [15,16,19,20] dem-
onstrate a strong correlation between a high level of constit-
utive Janus kinase activity and carcinogenesis. A classic char-
acteristic of tumorigenic oncogenes is the ability to stimulate 
DNA synthesis in NIH 3T3 cells under conditions of serum 
starvation. In this report, we test whether catalytically active 
forms of rat JAK2 possess an oncogenic potential by over-
expressing the kinase in NIH 3T3 cells. 
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2. Materials and methods 
2.1. Cell culture 
NIH 3T3 cells (2xl05) were plated onto etched glass coverslips 
which were immersed in 35-mm culture dishes containing Dulbecco's 
modified essential medium (DMEM) supplemented with 10% heat-
inactivated fetal bovine serum (FBS), 50 U of penicillin/ml, and 50 
μg of streptomycin/ml. Cells were grown to confluency at 37°C, the 
medium was replaced with DMEM containing 0.5% heat-inactivated 
FBS, and then cultures were incubated 24 h before microinjection. 
2.2. Construction of expression vectors 
The expression vector pcDNA3:rJAK2 was created by subcloning a 
3.7 kb cDNA fragment encoding the rat JAK2 [21] into the Notl and 
Apal restriction sites of pcDNA3 (Invitrogen). This vector contained a 
5' untranslated region of approximately 300 bp. The expression vector 
pcDNA3:(NA661)rJAK2 was created by digesting pcDNA3:rJAK2 
with the restriction endonuclease BamHl, re-ligating the plasmid di-
gest mixture, then isolating a plasmid that lacked the BamHI frag-
ment at the 5' end of the jak2 coding region. 
2.3. Microinjection of cells and assay for DNA synthesis 
Microinjections and DNA synthesis assays were performed as pre-
viously described [22]. Briefly, plasmid DNA (100^100 μg/ml) or phos-
phate-buffered saline (PBS), pH 7.4, was loaded into glass capillary 
micropipettes made with an automatic P80/PC micropipette puller 
(Sutter Instruments, Co.). A specific area on the coverslip was 
scratched to localize the injection area, and 100-200 quiescent cells 
were microinjected (3-7 X10-12 ml/cell) with coded samples using a 
computerized Eppendorf microinjection system. The coverslips were 
maintained in low fetal calf serum (FCS, 0.5%) containing media for 
approximately 18 h before the addition of [3H]thymidine (0.5 μθ/piιΐ, 
Amersham) for a 4 h pulse. The coverslips were washed with PBS, 
fixed in 2.5% glutaraldehyde (v/v PBS), coated with nuclear tracking 
emulsion (NTB2, Kodak), subjected to autoradiography for 36 h, and 
the cells were stained with Geisma. Every microinjected cell within the 
scratched area of the coverslip was identified by the computer pro-
gram and scored for induction of DNA synthesis and the cells were 
photographed at 100X. Fold-induction of DNA synthesis is a meas-
ure of the sample's ability to drive growth-arrested Go fibroblasts into 
S phase. It is defined as the ratio of microinjected cells that incorpo-
rate [3H]thymidine into DNA divided by the ratio of uninjected cells 
near the injected area that incorporate [3H]thymidine into DNA. 
In experiments involving the use of AG-490, quiescent NIH 3T3 
cells were pre-incubated with 10 μΜ AG-490 (Calbiochem) 1 h prior 
to microinjection. Microinjected cells were maintained in the presence 
of 10 μΜ AG-490 in the dark for the duration of the DNA synthesis 
assay. 
3. Results and discussion 
NIH 3T3 cells which had been made quiescent by mainte-
nance in low-serum media were microinjected with either PBS, 
the expression vector pcDNA3, or pcDN A3-derived expres-
sion vectors encoding either JAK2 (pcDNA3:rJAK2) or the 
putative hyperactive form of JAK2 (pcDNA3:(NA661)r-
JAK2). The cells were then assayed for entry into S phase 
by their ability to incorporate [3H]thymidine into newly syn-
thesized DNA. A typical experimental set is shown in Fig. 1. 
The tabulated results of the microinjection series are presented 
in Table 1. Microinjection of either PBS or the expression 
Table 1 
Summary of results from microinjection experiments 
Sample Number of injected cells 
PBS control 1100 
pcDNA3:rIAK2 1700 
pcDNA3 control 1400 
pcDNA3: (NA661)rJAK2 1700 
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vector pcDNA3 results in only a small, but detectable, induc-
tion of DNA synthesis. Microinjection of PBS results in a 2.6-
fold induction of DNA synthesis relative to non-injected cells 
(Fig. 1, panel a). Microinjection of the parental pcDNA3 
vector results in a comparable 4.8-fold induction of DNA 
synthesis (Fig. 1, panel c). In contrast, microinjection of 
pcDNA3:rJAK2 into quiescent NIH 3T3 cells induced ap-
proximately a 30-fold increase in DNA synthesis (Fig. 1, panel 
b). Quiescent NIH 3T3 cells which were microinjected with 
pcDNA3:(NA661)rJAK2, which contains the catalytic core 
of the kinase, also exhibited a 30-fold increase in DNA syn-
thesis (Fig. 1, panel d). When the two forms of JAK2-express-
ing vectors were microinjected at high concentrations (¡=0.5-
2 fg DNA injected/cell), comparable increases in DNA syn-
thesis were observed. 
These results suggested that the microinjection of plasmids 
encoding active isoforms of JAK2 resulted in the production 
of active Janus kinases which in turn induced proliferation, 
perhaps through the phosphorylation of key signal transduc-
tion components. In order to ascertain that JAK2 kinase ac-
tivity was essential for the induction of DNA synthesis, we 
repeated the microinjection experiments in the presence of a 
JAK2-selective inhibitor, AG-490 [16]. AG-490 is a tyrphostin 
which has an antiproliferative effect on leukaemic pre-B cells 
but not on normal cells. AG-490 selectively inhibits the kinase 
activity of JAK2, but does not inhibit other kinases such as 
Lck, Lyn, Btk, Syk or Src. 
In Table 2 we present the results of experiments in 
which the expression vectors pcDNA3:rJAK2 or 
pcDNA3:(NA661)rJAK2 were microinjected into quiescent 
NIH 3T3 cells in the presence or absence of 10 μΜ AG-
490. As before, there was a marked increase in DNA synthesis 
following the microinjection of either expression vector in the 
absence of AG-490. The presence of 10 μΜ AG-490 com-
pletely blocked the ability of the pcDNA3:rJAK2 expression 
vector to induce DNA synthesis. Quite interestingly, the pres-
ence of 10 μΜ AG-490 did not significantly inhibit the induc-
tion of DNA synthesis by microinjected pcDNA3:(NA661)r-
JAK2. While we have not yet completely characterized this 
unexpected finding, it suggests that the mechanism of AG-490 
inhibition may involve the putative inhibitory domain of 
JAK2 [12], rather than a direct interaction of the tyrphostin 
with the JAK2 catalytic domain. 
Many of the growth factors and cytokines which induce the 
activation of JAK2 also induce proliferation in many different 
target cells. Prolactin, for example, stimulates JAK2 activa-
tion and proliferation in Nb2-llC cells, and interleukin-3 
stimulates both JAK2 activation and proliferation in Baf3 
cells. Growth hormone couples to the activation of JAK2 in 
3T3 cells [6]. Most proliferation assays traditionally follow the 
entry of quiescent cells from G0 phase into S phase via the 
incorporation of [3H]thymidine into newly synthesized DNA. 
The microinjection studies presented in this paper indicate 
Fold-induction of DNA synthesis 
2.6 (± 2.1) 
29.5 (±11.3) 
4.8 (± 3.1) 
30.1 (±10.6) 
Parenthetical value is the standard deviation of measurement. 
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Fig. 1. rJAK2 and (NA661)rJAK2 induce DNA synthesis after microinjection into quiescent NIH 3T3 cells. NIH 3T3 fibroblasts were made 
quiescent by growth in low-serum medium (0.5% fetal calf serum) for 24 h before microinjection. Approximately 100 cells were injected with 
~5X10"12 ml of either PBS control (a), pcDNA3:rJAK2 (b), pcDNA3 vector control (c), or pcDNA3:(NA661)rJAK2 (d). The concentration 
of microinjected DNA was 300 μg/ml. Cells were administered a 4 h pulse of [3H]thymidine 18 h after microinjection, then washed, fixed, auto-
radiographed, stained with Geisma, and photographed at 100X. 
that the presence of sufficient JAK2 in the cell may circum-
vent the need for an exogenous activating cytokine or growth 
factor in the stimulation of DNA synthesis. Based on immu-
nocytochemical staining 8 h after microinjection, we observed 
a 2^1-fold increase in JAK2 protein in cells microinjected with 
either pcDNA3:(NA661)rJAK2 or pcDNA3:rJAK2 as com-
pared to non-injected or pcDNA3-injected cells (data not 
shown). Constitutively active JAK2, resulting from either an 
overexpression of wild-type JAK2 or from a defect in the 
putative regulatory domain, may therefore escape normal re-
ceptor-coupled regulation and therefore be considered onco-
genic. This is indeed consistent with the observations related 
to the Tumorous-lethal mutation in hopscotch [15], and to the 
potential role of JAK2 in ALL [16]. 
Microinjection studies of other proto-oncogenes and onco-
genes report fold-increases in DNA synthesis which are com-
parable to the fold-increases we demonstrate here for JAK2. 
Both the gamma and beta isozymes of phospholipase C can 
induce approximately 23-fold increases in DNA synthesis [22]. 
The HER-2/»ew promoter binding factor (HPBF) induces only 
a 12-fold induction of DNA synthesis when microinjected into 
quiescent NIH 3T3 cells; when HPBF is co-injected with c-
Ras the combination induces a 25-fold increase in DNA syn-
thesis [23]. While the full-length c-Raf protein did not induce 
DNA synthesis in quiescent NIH 3T3 cells, mutant forms of 
c-Raf which lacked the amino terminus did induce DNA syn-
thesis 22-26-fold after microinjection into such cells [24]. Our 
results demonstrate that DNA synthesis is stimulated in se-
rum-starved NIH 3T3 cells by the overexpression of JAK2 
which apparently circumvents the normal role for cytokine 
or growth factor involvement in initiating the G0/S cell cycle 
transition. Moreover, when JAK2 is compared with other 
proto-oncogenes and oncogenes which induce DNA synthesis 
in quiescent NIH 3T3 cells, it is comparable to those that 
Table 2 








the presence or absence of 10 μΜ AG-490 
(without inhibitor) Fold-induction of DNA 
3.8 (±1.2) 
22.4 (±4.5) 
synthesis (+10 μΜ AG -490) 
500-600 cells were injected in each of the four data sets. Parenthetical value is the standard deviation of measurement 
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induce a high level of D N A synthesis (20-30-fold induction), 
rather than a moderate response (10-20-fold induction). 
Although the breadth of the spectrum of cells which may be 
susceptible to JAK-mediated transformation is unknown, it 
appears that mutat ions in the jak2 proto-oncogene resulting 
in either JAK2 overexpression or constitutive JAK2 activation 
clearly have oncogenic potential. 
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